HIA
ADMA icon

HFM Investment Advisors’s ADMA Biologics ADMA Stock Holding History

HFM Investment Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51 Sell
6
-1
-14% -$9 ﹤0.01% 1269
2026
Q1 		$63 Sell
7
-2
-22% -$32 ﹤0.01% 1157
2025
Q4 		$165 Buy
9
+4
+80% +$67 ﹤0.01% 1074
2025
Q3 		$73 Sell
5
-11
-69% -$189 ﹤0.01% 1193
2025
Q2 		$291 Buy
16
+13
+433% +$265 ﹤0.01% 857
2025
Q1 		$60 Buy
+3
New +$52 ﹤0.01% 1001

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HFM Investment Advisors's ADMA Position: Q2 2026 in Review

HFM Investment Advisors reduced its ADMA Biologics (ADMA) stake by 14% in Q2 2026, selling an estimated $9 and leaving 6 shares worth $51. The position accounts for ﹤0.01% of the portfolio, ranked #1269.

HFM Investment Advisors first reported a position in ADMA in Q1 2025 and has held it in 6 quarters since. The position peaked at $291 in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • HFM Investment Advisors held 6 shares of ADMA Biologics worth $51 as of Q2 2026.
  • HFM Investment Advisors sold 1 ADMA Biologics share in Q2 2026, an estimated $9.
  • ADMA Biologics made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #1269 holding.
  • HFM Investment Advisors first reported a position in ADMA Biologics in Q1 2025 and has held it in 6 quarters since.
  • HFM Investment Advisors's ADMA Biologics position peaked at $291 in Q2 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.